Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Acetate SCHEMBL5273475 | 0.87 | ALDH1A1 (0.52) | LMNAALDH1A1HSD17B10THRBATM | |
| Ethyl Acetate SCHEMBL1121357 | 0.86 | ALDH1A1 (0.50) | LMNAALDH1A1HSD17B10THRBATM | |
| SCHEMBL28283022 | 0.84 | LMNA (0.41) | LMNAALDH1A1THRBATML3MBTL1 | |
| Ethyl Acetate SCHEMBL3896439 | 0.83 | ALDH1A1 (0.47) | LMNAALDH1A1HSD17B10THRBATM | |
| Acetic Acid SCHEMBL7705514 | 0.82 | EPHX1 (0.47) | LMNAALDH1A1EPHX1HPGDKMT2A | |
| Ethyl Acetate SCHEMBL28258502 | 0.81 | ALDH1A1 (0.54) | LMNAALDH1A1HSD17B10THRBATM | |
| Ethyl Acetate SCHEMBL1058290 | 0.81 | ALDH1A1 (0.54) | LMNAALDH1A1HSD17B10THRBATM | |
| Hexyl Acetate SCHEMBL30762264 | 0.81 | ALDH1A1 (0.49) | LMNAALDH1A1EPHX1EPHX2 | |
| Ethyl Acetate SCHEMBL11626907 | 0.81 | ALDH1A1 (0.48) | LMNAALDH1A1HSD17B10THRBATM | |
| SCHEMBL14679380 | 0.80 | EPHX1 (0.52) | LMNAALDH1A1EPHX1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384115-B2 | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210147469-A1 | NUCLEAR SULFATED OXYSTEROL, POTENT REGULATOR OF LIPID HOMEOSTASIS, FOR THERAPY OF HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDES, FATTY LIVER DISEASES, AND ATHEROSCLEROSIS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2021-05-20 | — | — | US | disclosed |
| CN-108634362-B | Preparation method and application of composite type tobacco flavor enhancer | 江西中烟工业有限责任公司 | 2020-12-29 | — | — | CN | disclosed |
| US-10844089-B2 | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190169225-A1 | Nuclear Sulfated Oxysterol, Potent Regulator of Lipid Homeostasis, for Therapy of Hypercholesterolemia, Hypertriglycerides, Fatty Liver Diseases, and Atherosclerosis | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2019-06-06 | — | — | US | disclosed |
| US-20180346509-A9 | NUCLEAR SULFATED OXYSTEROL, POTENT REGULATOR OF LIPID HOMEOSTASIS, FOR THERAPY OF HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDES, FATTY LIVER DISEASES, AND ATHEROSCLEROSIS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2018-12-06 | — | — | US | disclosed |
| US-10144759-B2 | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2018-12-04 | — | — | US | disclosed |
| US-20160264615-A1 | Nuclear Sulfated Oxysterol, Potent Regulator of Lipid Homeostasis, for Therapy of Hypercholesterolemia, Hypertriglycerides, Fatty Liver Diseases, and Atherosclerosis | UNIV VIRGINIA COMMONWEALTH (US) | 2016-09-15 | — | — | US | disclosed |
| US-9382306-B2 | Octapeptide compounds derived from somatostatin and the therapeutic use thereof | IPSEN PHARMA S.A.S. (FR) | 2016-07-05 | — | — | US | disclosed |
| US-9321802-B2 | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2016-04-26 | — | — | US | disclosed |
| US-4211841-A | 3AA-H-4A-/3-PROPIONIC ACID/-7AB-METHYLHEXAHYDRO-1,5-INDANEDIONE | THE UPJOHN COMPANY (US) | 1980-07-08 | — | — | US | disclosed |
| US-4125712-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-11-14 | — | — | US | disclosed |
| US-4125713-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-11-14 | — | — | US | disclosed |
| US-4100348-A | POLYURETHANES, ALKYD RESINS, HIGH GLASS TRANSITION TEMPERATURE | CIBA-GEIGY CORPORATION (US) | 1978-07-11 | — | — | US | disclosed |
| US-4062729-A | Microbial transformation of steroids | THE UPJOHN COMPANY (US) | 1977-12-13 | — | — | US | disclosed |
| US-4013688-A | STEROIDS | THE UPJOHN COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
| US-3948981-A | PROSTAGLANDIN | THE UPJOHN COMPANY (US) | 1976-04-06 | — | — | US | disclosed |
| US-3933891-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
| US-3931284-A | 11β-PGE2 compounds | THE UPJOHN COMPANY (US) | 1976-01-06 | — | — | US | disclosed |
| US-3931283-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147469-A1 | NUCLEAR SULFATED OXYSTEROL, POTENT REGULATOR OF LIPID HOMEOSTASIS, FOR THERAPY OF HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDES, FATTY LIVER DISEASES, AND ATHEROSCLEROSIS | NR1H3, NR1H2, SREBF1 | LMNA 3048/4885ALDH1A1 3676/4885HSD17B10 56/4885 |
| US-20160264615-A1 | Nuclear Sulfated Oxysterol, Potent Regulator of Lipid Homeostasis, for Therapy of Hypercholesterolemia, Hypertriglycerides, Fatty Liver Diseases, and Atherosclerosis | NR1H3, NR1H2, SREBF1 | LMNA 3048/4885ALDH1A1 3676/4885HSD17B10 56/4885 |
| US-20190169225-A1 | Nuclear Sulfated Oxysterol, Potent Regulator of Lipid Homeostasis, for Therapy of Hypercholesterolemia, Hypertriglycerides, Fatty Liver Diseases, and Atherosclerosis | NR1H3, NR1H2, SREBF1 | LMNA 3048/4885ALDH1A1 3676/4885HSD17B10 56/4885 |
| US-10844089-B2 | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis | NR1H3, NR1H2, SREBF1 | LMNA 3048/4885ALDH1A1 3676/4885HSD17B10 56/4885 |
| US-11384115-B2 | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis | NR1H3, NR1H2, SREBF1 | LMNA 3048/4885ALDH1A1 3676/4885HSD17B10 56/4885 |
| US-20180346509-A9 | NUCLEAR SULFATED OXYSTEROL, POTENT REGULATOR OF LIPID HOMEOSTASIS, FOR THERAPY OF HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDES, FATTY LIVER DISEASES, AND ATHEROSCLEROSIS | NR1H3, NR1H2, SREBF1 | LMNA 3048/4885ALDH1A1 3676/4885HSD17B10 56/4885 |
| US-10144759-B2 | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis | NR1H3, NR1H2, SREBF1 | LMNA 3048/4885ALDH1A1 3676/4885HSD17B10 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.